What are embryonic stem cells?
Embryonic stem cells are pluripotent cells taken from an early-stage embryo, at the blastocyst stage, days after fertilization. They can become any tissue in the human body, and they divide indefinitely in culture. The first human lines were derived in 1998 in a Science paper from James Thomson's laboratory, and that single publication reorganised biology and ethics at the same time.
Understanding them matters even though they are not something you will be offered, because embryonic cells set the standard everything else in regenerative medicine is measured against, and the field's long detour around them explains why the cells you can actually receive are what they are.
Why they were the gold standard
Two properties made embryonic cells extraordinary. True pluripotency: they can form tissue from all three germ layers, which no adult stem cell reliably does. And unlimited self-renewal: a single line can be grown indefinitely, supplying material forever.
Adult stem cells, including the MSCs covered across this library, are multipotent rather than pluripotent, with a narrower range and a finite culture lifespan. That is not a flaw so much as a different job description, and it is why researchers wanted embryonic cells for the problems that require building tissue rather than sending signals.
The two problems
The ethical problem is the one everyone knows: deriving the cells destroys the embryo. That is a genuine moral question people answer differently, it drove funding restrictions and legal limits across countries, and it slowed the field for the better part of two decades.
The scientific problems are less discussed and just as constraining. Embryonic cells are donor tissue, so recipients face immune rejection questions. Their pluripotency carries teratoma risk, exactly as with iPSCs. And supply depends on donated embryos, which is neither scalable nor comfortable as a manufacturing base.
What the human trials showed
The clinical work is real and concentrated in the eye, which is an unusually good testing ground: accessible, partly immune-privileged, and with vision as an objective endpoint.
The landmark result came in the Lancet in 2015, reporting follow-up of two open-label phase 1/2 studies in which human embryonic stem cell-derived retinal pigment epithelium was transplanted into patients with age-related macular degeneration and Stargardt's macular dystrophy. It demonstrated medium-term safety and graft survival, the first substantial evidence that a therapy made from embryonic cells could be given to people without disaster.
Work has continued in that direction, including studies addressing the surgical and disease-specific factors that determine whether such transplants succeed in wet age-related macular degeneration, and broader reviews of retinal regeneration through stem cell therapy. Retina remains the most advanced application of embryonic-derived cells in humans.
Why the field moved on
In 2006 and 2007, the Yamanaka factors made it possible to produce pluripotent cells from an adult skin sample. That single technical advance dissolved the ethical objection, removed the supply constraint, and offered patient matching that donated embryos never could.
Research funding and attention followed almost immediately, which is why induced pluripotent cells now dominate the pluripotent conversation and embryonic lines are used mostly as the reference standard against which iPSC quality is judged. The honest summary is that the field found a technically superior route to the same biology, and the ethical relief was a bonus rather than the driver.
What this means for you
You will not be offered embryonic stem cell therapy. Outside a handful of registered ophthalmology trials, it does not exist as treatment anywhere, and any clinic using the term is almost certainly describing something else, most often cord-derived or other adult cells that have no embryonic origin at all.
That confusion is worth naming plainly, because it cuts both ways: some patients avoid legitimate cord-tissue therapy believing it involves embryos, and some clinics borrow the prestige of the term. Cord tissue comes from a live birth, and the cells covered across this library, from MSCs to exosomes, are adult or perinatal, never embryonic.
The pros and the cons
What made them valuable
- True pluripotency: any tissue in the body, from all three germ layers.
- Unlimited self-renewal from a single established line.
- The reference standard against which other pluripotent cells are measured.
- Real human trial evidence of safety and graft survival in retinal disease.
Why they were superseded
- Derivation destroys the embryo, an unresolved moral objection that shaped law and funding.
- Donor tissue, so immune considerations apply.
- Teratoma risk inherent to the pluripotent state.
- iPSCs deliver comparable biology from a skin sample, with patient matching.
Worth knowing
- No embryonic stem cell therapy is commercially available anywhere.
- Cord tissue is not embryonic; it comes from a healthy live birth.
- The retina is where the human evidence lives, and it is early-phase.
- A clinic claiming embryonic cells is a signal to ask exactly what is in the vial.
How the history shaped the present
The embryonic era left three legacies worth carrying forward. It established that pluripotent-derived tissue can be transplanted into people safely enough to justify continuing, in the eye at least. It built the entire safety apparatus, purification, tumorigenicity testing, differentiation protocols, that iPSC therapies now inherit. And its ethical constraints created the pressure that produced reprogramming, one of the clearest cases in modern science of a moral obstacle forcing a better technical solution.
What the key studies tested
Our framing rule for evidence: a study tests one product, in one population, on one endpoint. Where the evidence sits:
Foundational science
Thomson 1998: the first human embryonic stem cell lines.
Early trials
hESC-derived retinal pigment epithelium in macular degeneration and Stargardt's dystrophy.
Late-stage trials
None.
Approved uses
None, anywhere.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Are umbilical cord stem cells embryonic?
No, and this is the most common confusion in the field. Cord tissue is collected after a healthy full-term live birth from tissue that would otherwise be discarded; no embryo is involved at any point. Cord-derived MSCs are adult-type multipotent cells, not pluripotent embryonic ones, and they are what most regenerative clinics actually use.
Can I receive embryonic stem cell treatment?
Realistically, no. Outside a small number of registered ophthalmology trials, embryonic-derived therapy is not available anywhere, and no product is approved. A clinic advertising embryonic stem cells is describing something else or overstating what it has, and the right response is to ask precisely what the cells are and where they came from.
Why did researchers move to iPSCs?
Because reprogramming delivered the same pluripotent biology from an adult skin sample, with no embryo, no supply ceiling, and the possibility of patient matching. That was a technical improvement as much as an ethical one, and once it existed in human cells in 2007 the field reorganised around it within a few years.
Did embryonic stem cell research achieve anything clinically?
Yes, principally in the eye. Transplants of embryonic-derived retinal pigment epithelium in macular degeneration and Stargardt's dystrophy demonstrated medium-term safety and graft survival in published phase 1/2 follow-up, and that work built the safety and manufacturing playbook that every pluripotent-derived therapy, including iPSC programs, now uses.
What to take away
If you remember five things from this article, make them these:
- Embryonic stem cells are truly pluripotent and endlessly renewable, which is why they set the standard.
- Their derivation destroys an embryo, an objection that shaped decades of law, funding, and research direction.
- Human trials in retinal disease showed safety and graft survival, the field's main clinical legacy.
- iPSCs superseded them by delivering the same biology from a skin sample, with patient matching.
- Cord-derived cells are not embryonic, and no embryonic therapy is commercially available anywhere.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Embryonic stem cell research is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.